JP2023524912A5 - - Google Patents

Info

Publication number
JP2023524912A5
JP2023524912A5 JP2023509462A JP2023509462A JP2023524912A5 JP 2023524912 A5 JP2023524912 A5 JP 2023524912A5 JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023524912 A5 JP2023524912 A5 JP 2023524912A5
Authority
JP
Japan
Prior art keywords
approximately
period
pharmaceutical composition
effective amount
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524912A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028726 external-priority patent/WO2021216936A1/en
Publication of JP2023524912A publication Critical patent/JP2023524912A/ja
Publication of JP2023524912A5 publication Critical patent/JP2023524912A5/ja
Pending legal-status Critical Current

Links

JP2023509462A 2020-04-23 2021-04-22 4’-チオ-5-アザ-2’-デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 Pending JP2023524912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (2)

Publication Number Publication Date
JP2023524912A JP2023524912A (ja) 2023-06-13
JP2023524912A5 true JP2023524912A5 (enExample) 2024-05-01

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509462A Pending JP2023524912A (ja) 2020-04-23 2021-04-22 4’-チオ-5-アザ-2’-デオキシシチジンを使用して血液がんを治療するための組成物及びその使用

Country Status (8)

Country Link
US (2) US12208112B2 (enExample)
EP (1) EP4138843A4 (enExample)
JP (1) JP2023524912A (enExample)
KR (1) KR20230004768A (enExample)
CN (1) CN115768432A (enExample)
AU (1) AU2021260964A1 (enExample)
CA (1) CA3176543A1 (enExample)
WO (1) WO2021216936A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210363170A1 (en) * 2018-04-19 2021-11-25 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
MX2024004801A (es) 2021-10-19 2024-06-28 Akirabio Inc Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.
KR20240139581A (ko) * 2023-03-14 2024-09-23 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
WO2025100762A1 (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
NZ509405A (en) 1998-07-23 2004-10-29 Southern Res Inst Preparation of 1-(4-thio-thioarabinofuranosyl) cytosine derivatives and their use as anticancer agents and DNA replication inhibitors
US20060127990A1 (en) 2002-08-22 2006-06-15 Geneticlab Co., Ltd 4'-thionucleotide
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109383A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
CN106687139A (zh) * 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
CN106661077B (zh) 2015-04-03 2019-02-12 四川科伦博泰生物医药股份有限公司 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
EP3303361A1 (en) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 2’-デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
US20210363170A1 (en) 2018-04-19 2021-11-25 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2020068657A1 (en) 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Similar Documents

Publication Publication Date Title
JP2001522833A5 (enExample)
JP6342960B2 (ja) 化学療法誘導嘔吐を治療するためのパロノセトロン
EP1951046B1 (en) Methods to enhance chemotherapy
US20090306051A1 (en) Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
US20200222379A1 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
AU2002343548B8 (en) Improved use of antitumoral compound in cancer therapy
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2007534730A (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
CZ301482B6 (cs) Prostredky a použití ET743 k lécbe rakoviny
JP2021522197A5 (enExample)
US20020198137A1 (en) Antineoplastic combinations
EA007530B1 (ru) Противоопухолевые комбинации
WO2013054153A1 (en) Nutlin compounds for use in he treatment of pulmonary hypertension
JP2023535724A5 (enExample)
CN120284929A (zh) 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JP2024506847A5 (enExample)
JP2024516848A (ja) 血液がんを処置する方法
EA016873B1 (ru) Применение для лечения лейкемии
JP2008514721A5 (enExample)
JP2008514721A (ja) 治療方法
CN1720053A (zh) 降低抗癌药物毒性的方法
CN116509865B (zh) 硝酮类化合物在制备预防或治疗骨髓抑制药物中的应用
JP2004026811A (ja) ビタミンd3誘導体を含有する抗癌作用を増強させるための薬剤